You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Closed-loop laryngeal pacing for voice restoration

    SBC: RIPPLE LLC            Topic: NIDCD

    Project Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth

    SBC: DARE BIOSCIENCE, INC.            Topic: NICHD

    In the United States, one in ten babies is born prematurely. The earlier in pregnancy a baby is born, the more likely they will have an extended hospital stay, as well as serious health complications such as respiratory distress syndrome, necrotizing enterocolitis, deafness, vision problems and cerebral palsy. Maternal stress is a well-established risk factor for preterm birth, and recent studies ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY Acute disseminated encephalomyelitis (ADEM) is an acute autoimmune disease that can present with fever and ataxia as well as loss of consciousness and coma. ADEM largely affects children, is driven by T and B lymphocytes aberrantly activated against a myelin antigen, and is strongly associated with a prior infection or immunization. There is no FDA-approved therapy for the treatmen ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. AIVIS: Next Generation Vigilant Information Seeking Artificial Intelligence-based Clinical Decision Support for Sepsis

    SBC: Healcisio, Inc.            Topic: NIAID

    Abstract Sepsis, a heterogeneous syndrome characterized by whole-body inflammation caused by the body's response to an infection, is the most expensive and deadly condition treated in hospitals, with over 270,000 cases of sepsis-related deaths in the U.S. alone. The cornerstones of optimal sepsis care are early recognition accompanied by appropriate antimicrobial therapy, and use of evidence-based ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis

    SBC: TARN BIOSCIENCES, INC.            Topic: NIAID

    Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Water-based liquid embolic agent for the treatment of vascular rich tumors

    SBC: AQUATEX MEDICAL INC            Topic: 102

    AquaTeX Medical is developing a novel liquid embolic material (LEM) - Aqua Embolic System (AES) - to improve cancer treatment. AES is designed to occlude feeding vessels of hypervascular tumors with superior efficacy and excellent biocompatibility as compared to other trans-arterial embolization (TAE) materials.TAE is a catheter-based treatment to treat hypervascular tumors. Embolic materials are ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Leptospirosis Vaccine Development

    SBC: Luna Bioscience, Inc.            Topic: NIAID

    Summary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A digital tool for monitoring speech decline in ALS

    SBC: MODALITY.AI , INC            Topic: NIDCD

    PROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY Lupus is a chronic, systemic autoimmune disease in which cells of the immune system attack organ systems throughout the body including the kidneys, brain, and lungs and that presents heterogeneously with symptoms that can include fever, arthritis, alopecia, stroke, and heart attack. Lupus is driven by autoreactive B and CD4 T cells with a particular role for TfH and TH17 CD4 T cell ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government